Published on | 1 year ago
Programmes Digital, Industry & Space Horizon Europe HorizonEU L+F AI ContinentThe video at the end of this article contains a training on Artificial Intelligence (AI) in Horizon Europe, given by Cristina Contero Almagro (Aphaia). Over the past five years, Europe has prioritized AI as a means to enhance its competitive edge. This training provides an overview of key milestones in AI regulation, including the ethics guidelines for trustworthy AI, the Assessment List for justworthy AI, and the proposed Artificial Intelligence Act. The focus lies on what you can do within the frame of self-assessment, and is especially relevant for AI-heavy projects.
You can find below the basic information (and links to more information) of the most important documents.
The foundation of AI regulation began with the Ethics Guidelines for Trustworthy AI in 2018. The guidelines defined trustworthy AI based on three components: legality, ethical adherence, and robustness. To achieve trustworthy AI, compliance with laws, ethical principles, and robust technical and societal frameworks is essential to prevent unintended harm and enhance societal acceptance of AI technologies.
Following the ethics guidelines, the Assessment List for Trustworthy AI was published in late 2019, serving as an operational tool. It outlines specific requirements and questions related to ethical AI, aiding applicants and stakeholders in understanding and assessing their projects' adherence to ethical standards. While not offering definitions, it prompts critical self-reflection to ensure ethical considerations are adequately addressed.
The Artificial Intelligence Act, although not yet applicable, represents a significant step in AI regulation. It categorizes AI systems into four risk levels: acceptable risk, high risk (e.g., critical infrastructures), limited risk (e.g., standard websites), and minimal risk (e.g., video games). Each category corresponds to distinct regulatory requirements, reinforcing transparency and accountability, especially in high-risk applications.
Privacy and data governance are key aspects linked to principles of preventing harm, fairness, and accountability. This requirement emphasizes the critical role of data management and privacy protections. Ensuring compliance with data privacy regulations is vital in the majority of AI projects, highlighting the need for familiarity with these aspects in AI development and implementation.
Understanding the evolving landscape of AI regulation in Horizon Europe is fundamental for successful project applications. The Ethics Guidelines, Assessment List, and proposed Artificial Intelligence Act provide a roadmap for developers and stakeholders to navigate the legal and ethical implications of AI. Addressing privacy and data governance concerns is equally vital to ensure responsible and effective AI deployment within the European context.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space AI Continent Cybersecurity
The European Commission has opened a call for evidence to collect research and best practices on how to simplify its legislation, especially when it comes to data, cybersecurity and artificial intelligence (AI). This initiative is part of the Commission’s simplification agenda and efforts to create a more favourable business environment, by... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.